Literature DB >> 22038859

Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia.

Karl J Madaras-Kelly1, Richard E Remington, Vincent S Fan, Kevin L Sloan.   

Abstract

OBJECTIVE: To develop and validate a model to predict resistance to community-acquired pneumonia antibiotics (CAP-resistance) among patients with healthcare-associated pneumonia (HCAP), and to compare the model's predictive performance to a model including only guideline-defined criteria for HCAP.
DESIGN: Retrospective cohort study.
SETTING: Six Veterans Affairs Medical Centers in the northwestern United States. PATIENTS: Culture-positive inpatients with HCAP. MEASUREMENTS: Patients were identified based upon guideline-defined criteria for HCAP. Relevant cultures obtained within 48 hours of admission were assessed to determine bacteriology and antibiotic susceptibility. Medical records for the year preceding admission were assessed to develop predictive models of CAP-resistance with logistic regression. The predictive performance of cohort-developed and guideline-defined models was compared.
RESULTS: CAP-resistant organisms were identified in 118 of 375 culture-positive patients. Of guideline-defined criteria, CAP-resistance was associated (odds ratio (OR) [95% confidence interval (CI)]) with: admission from nursing home (2.6 [1.6-4.4]); recent antibiotic exposure (1.7 [1.0-2.8]); and prior hospitalization (1.6 [1.0-2.6]). In the cohort-developed model, CAP-resistance was associated with: admission from nursing home or recent nursing home discharge (2.3 [1.4-3.8]); positive methicillin-resistant Staphylococcus aureus (MRSA) history within 90 days of admission (6.4 [2.6-17.8]) or 91-365 days (2.3 [0.9-5.9]); cephalosporin exposure (1.8 [1.1-2.9]); recent infusion therapy (1.9 [1.0-3.5]); diabetes (1.7 [1.0-2.8]); and intensive care unit (ICU) admission (1.6 [1.0-2.6]). Area under the receiver operating characteristic curve (aROC [95% CI]) for the cohort-developed model (0.71 [0.65-0.77]) was significantly higher than for the guideline-defined model (0.63 [0.57-0.69]) (P = 0.01).
CONCLUSIONS: Select guideline-defined criteria predicted CAP-resistance. A cohort-developed model based primarily on prior MRSA history, nursing home residence, and specific antibiotic exposures provided improved prediction of CAP-resistant organisms in HCAP.
Copyright © 2011 Society of Hospital Medicine.

Entities:  

Mesh:

Year:  2011        PMID: 22038859      PMCID: PMC4778425          DOI: 10.1002/jhm.942

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  25 in total

1.  Beyond beta: lessons learned from implementation of the Department of Veterans Affairs Methicillin-Resistant Staphylococcus aureus Prevention Initiative.

Authors:  Amanda G Garcia-Williams; LaToya J Miller; Kelly H Burkitt; Timothy Cuerdon; Rajiv Jain; Michael J Fine; John A Jernigan; Ronda L Sinkowitz-Cochran
Journal:  Infect Control Hosp Epidemiol       Date:  2010-07       Impact factor: 3.254

2.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

3.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?

Authors:  A C Galles; R N Jones; H S Sader
Journal:  J Chemother       Date:  2008-02       Impact factor: 1.714

5.  Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.

Authors:  J A Hoogkamp-Korstanje; J Roelofs-Willemse
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

6.  Accuracy of administrative data for identifying patients with pneumonia.

Authors:  Dominik Aronsky; Peter J Haug; Charles Lagor; Nathan C Dean
Journal:  Am J Med Qual       Date:  2005 Nov-Dec       Impact factor: 1.852

7.  Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Daryl J Hoban; Samuel K Bouchillon; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2007-04       Impact factor: 2.803

8.  Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission.

Authors:  S Nseir; G Grailles; A Soury-Lavergne; F Minacori; I Alves; A Durocher
Journal:  Clin Microbiol Infect       Date:  2009-08-20       Impact factor: 8.067

9.  Colonization and infection with antibiotic-resistant bacteria in a long-term care facility.

Authors:  M S Terpenning; S F Bradley; J Y Wan; C E Chenoweth; K A Jorgensen; C A Kauffman
Journal:  J Am Geriatr Soc       Date:  1994-10       Impact factor: 5.562

Review 10.  What are the important risk factors for healthcare-associated pneumonia?

Authors:  David S Poch; David E Ost
Journal:  Semin Respir Crit Care Med       Date:  2009-02-06       Impact factor: 3.119

View more
  9 in total

1.  Guideline-based antibiotics and mortality in healthcare-associated pneumonia.

Authors:  Karl J Madaras-Kelly; Richard E Remington; Kevin L Sloan; Vincent S Fan
Journal:  J Gen Intern Med       Date:  2012-03-07       Impact factor: 5.128

2.  Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.

Authors:  Russell T Attridge; Christopher R Frei; Mary Jo V Pugh; Kenneth A Lawson; Laurajo Ryan; Antonio Anzueto; Mark L Metersky; Marcos I Restrepo; Eric M Mortensen
Journal:  J Crit Care       Date:  2016-08-11       Impact factor: 3.425

3.  Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.

Authors:  Brandon J Webb; Kristin Dascomb; Edward Stenehjem; Holenarasipur R Vikram; Neera Agrwal; Kenneth Sakata; Kathryn Williams; Bruno Bockorny; Kavitha Bagavathy; Shireen Mirza; Mark Metersky; Nathan C Dean
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Treatment Trends and Outcomes in Healthcare-Associated Pneumonia.

Authors:  Sarah Haessler; Tara Lagu; Peter K Lindenauer; Daniel J Skiest; Aruna Priya; Penelope S Pekow; Marya D Zilberberg; Thomas L Higgins; Michael B Rothberg
Journal:  J Hosp Med       Date:  2017-11       Impact factor: 2.960

5.  Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.

Authors:  Christopher R Frei; Sylvie Rehani; Grace C Lee; Natalie K Boyd; Erene Attia; Ashley Pechal; Rachel S Britt; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2017-02-03       Impact factor: 4.705

Review 6.  Healthcare-associated Pneumonia and Aspiration Pneumonia.

Authors:  Kosaku Komiya; Hiroshi Ishii; Jun-Ichi Kadota
Journal:  Aging Dis       Date:  2014-02-08       Impact factor: 6.745

7.  Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.

Authors:  Barbara E Jones; Makoto M Jones; Benedikt Huttner; Gregory Stoddard; Kevin Antoine Brown; Vanessa W Stevens; Tom Greene; Brian Sauer; Karl Madaras-Kelly; Michael Rubin; Matthew Bidwell Goetz; Matthew Samore
Journal:  Clin Infect Dis       Date:  2015-07-29       Impact factor: 9.079

8.  A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study.

Authors:  Andrew A Quartin; Ernesto G Scerpella; Sailaja Puttagunta; Daniel H Kett
Journal:  BMC Infect Dis       Date:  2013-11-27       Impact factor: 3.090

9.  Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis.

Authors:  Rodrigo M Carrillo-Larco; Cecilia Anza-Ramírez; Giancarlo Saal-Zapata; David Villarreal-Zegarra; Jessica Hanae Zafra-Tanaka; Cesar Ugarte-Gil; Antonio Bernabé-Ortiz
Journal:  J Epidemiol Community Health       Date:  2021-07-29       Impact factor: 3.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.